In the body, molnupiravir is converted into a molecule that disrupts the genome of the SARS-CoV-2 virus, introducing some nucleotide mutations in its RNA - randomly changing some Cs to Ts and some ...

Tevogen recently reissued topline results from its Proof-of-Concept (POC) clinical trial, conducted at Thomas Jefferson University Hospital in Philadelphia. This trial assessed the safety and ...

In the study, published Sept. 18 in Nature Communications, researchers isolated drug-resistant strains of SARS-CoV-2 from people who had not cleared the virus after two to three months of ...

SARS2seq is a pipeline designed to process raw FastQ data from targeted SARS-CoV-2 sequencing and generate biologically correct consensus sequences of the SARS-CoV-2 genome.

“It might start becoming the top circulating lineage,” Rajnaranayam said, predicting XEC will take the rest of October and ...

10:45-11:15 SARS-CoV-2 Evolution on a Dynamic Immune Landscape 11:15-11:45 Hands-on (SARS-CoV-2 Evolution on a Dynamic Immune Landscape) ...

Europe has announced a €2 million project to research long COVID, following €100 million already invested since 2021. Is all ...

OPKO Health's receipt of the additional funding from BARDA is expected to explore the MSTAR platform to prepare for outbreaks and respond rapidly to emerging viral threats.

Executive summaryScientists are constantly trying to improve the use and efficiency of models in research. As such, they are ...

The BNT162b2 XBB1.5-adapted vaccine demonstrated lower effectiveness against JN.1 vs XBB sublineages, according to study findings.